Breakthrough pain variability has no impact on response to sublingual fentanyl tablets or placebo
Variability in baseline breakthrough pain (BTP) has no impact on the analgesic response to sublingual fentanyl tablets or placebo.
Variability in baseline breakthrough pain (BTP) has no impact on the analgesic response to sublingual fentanyl tablets or placebo.
Tapentadol ER does not significantly affect blood pressure (BP) or heart rate (HR) and thus, may be used for analgesia in patients with hypertension, study results reveal.
Researchers at the American Pain Society’s 30th Annual Scientific Meeting discussed data from a review of spontaneous adverse events reported with Embeda (morphine sulfate and naltrexone HCl) treatment, with a focus on events potentially related to product tampering.
Fulranumab no more efficacious than placebo for treating patients with chronic low back pain.
Fentanyl buccal tablet was more effective than traditional short-acting opioids for breakthrough pain in opioid-tolerant patients.
A capsaicin 8% patch significantly reduces pain in older patients with postherpetic neuralgia (PHN), a debilitating condition characterized by persistent pain following the healing of a herpes zoster rash.
Milnacipran treatment resulted in improvements in pain and global status regardless of baseline pain severity or fibromyalgia severity.
Duloxetine, pregabalin, and duloxetine + gabapentin were found to be safe and tolerable for the treatment of diabetic peripheral neuropathic pain.
Perioperative use of etoricoxib, a selective COX-2 inhibitor, in patients undergoing total abdominal hysterectomy significantly reduces both resting and elicited pain and opioid (morphine) consumption compared with placebo.
Tanezumab, a monoclonal antibody that inhibits nerve growth factor, is efficacious in treating osteoarthritis pain and may provide greater symptomatic improvement compared with placebo and naproxen.